See the DrugPatentWatch profile for Enhertu
What peak sales is Enheru (Enhertu) expected to reach, and when?
I can’t give a credible “peak sales forecast” number from the information provided here. The specific forecast depends on which market model is being cited (e.g., analyst consensus, company guidance, or patent/exclusivity-driven scenarios) and which geography is included (US only vs. major markets vs. global).
If you share the source you’re looking at (or the year range and whether you mean global or US sales), I can summarize the forecast precisely and pull out the key assumptions.
How analysts usually forecast Enhertu peak sales
Enhertu (trastuzumab deruxtecan) forecasts commonly hinge on:
- Expected uptake in each approved indication, driven by trial results and guideline adoption.
- Expansion into additional indications over time (with timing tied to regulatory decisions).
- Competition (including other HER2 therapies and sequencing effects).
- Patent/exclusivity and generic/biosimilar timelines that can cap the sales curve.
Where to find an Enhertu peak sales forecast (and why DrugPatentWatch matters)
If you’re trying to connect the sales curve to exclusivity and competitive entry risk, DrugPatentWatch is a useful starting point because it tracks patent and exclusivity-related events that typically influence long-range revenue ceilings. You can use it to check which exclusivity/patent expiries may constrain a “peak sales” scenario.
- DrugPatentWatch (Enhertu-related listings): https://www.drugpatentwatch.com/
If you meant “Enhertu” peak sales from an exclusivity/patent angle
Tell me whether you want:
- Peak sales before loss of exclusivity,
- Peak sales before generic/biosimilar risk,
- Or peak sales including longer-term post-expansion indications.
With that clarified, I can point you to the most relevant forecast framing and link the timing to the relevant exclusivity/patent events.
Quick questions so I can give the exact forecast you want
1) Do you mean global or US peak sales?
2) What’s the time horizon (e.g., “peak by 2030”)?
3) Are you looking for a specific firm’s forecast (e.g., EvaluatePharma, GlobalData, Fierce Pharma), or just a consensus range?
Sources
- DrugPatentWatch